FORA Capital’s Kezar Life Sciences KZR Stock Holding History

FORA Capital’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,434	Closed	-$74K	–	830
2020 Q2	$74K	Buy	+1,434	New	+$72.4K	0.03%	568

Other funds holding KZR

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FORA Capital's KZR Position: Q3 2020 in Review

FORA Capital sold out of Kezar Life Sciences (KZR) in Q3 2020, closing a stake of 1,434 shares — an estimated $74K sold.

FORA Capital first reported a position in KZR in Q2 2020 and held it in 1 quarter. The position peaked at $74K in Q2 2020. 78 funds tracked by Wall St. Rank hold KZR as of Q3 2020.

FORA Capital reported no remaining Kezar Life Sciences position as of Q3 2020 after selling out during the quarter.
FORA Capital sold 1,434 Kezar Life Sciences shares in Q3 2020, an estimated $74K.
FORA Capital first reported a position in Kezar Life Sciences in Q2 2020 and held it in 1 quarter.
FORA Capital's Kezar Life Sciences position peaked at $74K in Q2 2020.
78 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.